SymBio Pharma, Jan-Mar (1Q) Net Income Loss Widens

About Information Provided on This Site

The information provided on our website 'Kabutan.com' is not intended to constitute investment solicitation or investment advisory services.
All investment decisions should be made at your own discretion and judgment.
The data on our website is provided by Tokyo Stock Exchange, Osaka Exchange, Nagoya Securities Exchange, JPX Market Innovation & Research, Japannext, and other sources.
Copyright of the Nikkei Stock Average belongs to Nikkei Inc. Stock price charts displayed on Kabutan.com are provided solely for the purpose of reviewing historical price movements of the securities.
These charts neither suggest nor guarantee future price movements of the securities and do not constitute recommendations to buy or sell.
In our financial results coverage, the term 'Surprise Results' identifies securities that demonstrate a significant degree of surprise in their earnings announcements.
This significance is quantitatively assessed based on multiple factors, including: the nature of the announcement (full-year or quarterly results); types of revisions (earnings or dividend forecasts); and numerical analysis comparing the announced results with both the company's previous forecasts and historical performance.
The 'Surprise Ranking' presents these results in order of their calculated surprise factor. Please note that neither these results nor rankings are intended to suggest or guarantee future performance of the listed securities, nor should they be construed as recommendations to buy or sell.

Thu May 8, 2025 3:30 pm JST Earnings

4582 SymBio Pharmaceuticals Limited 【J-GAAP】

Earnings Report

SymBio Pharmaceuticals Limited <4582> [TSE Growth] announced its financial results after the market closed on May 8th (15:30). The consolidated net loss for the first quarter of the fiscal year ending December 2025 (January to March) expanded to a loss of 1.32 billion yen (compared to a loss of 0.77 billion yen in the same period last year).

In the most recent three-month period, from January to March (1Q), the operating profit/loss margin drastically worsened from -135.0% in the same period last year to -442.8%.

Kabutan News

Actual Results

Accumulated Results 1st Quarter

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Progress Rate vs. First Half	Announce	Accounting Standards
Jan - Mar, 2023	1,544	51	48	4	0.1	72.7	Apr 27, 2023	J-GAAP
Jan - Mar, 2024	597	-806	-727	-777	-18.0	ー	May 7, 2024	J-GAAP
Jan - Mar, 2025	264	-1,169	-1,288	-1,321	-28.0	ー	May 8, 2025	J-GAAP
YoY	-55.8%	-45.0%	-77.2%	-70.0%	-55.0%

Current Period Guidance

H1 Results

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Jan - Jun, 2024	1,284	-1,719	-1,481	-1,541	-34.8	0	Aug 1, 2024	J-GAAP
Jan - Jun, 2025 Guidance	ー	ー	ー	ー	－	0	Feb 6, 2025	J-GAAP
YoY	－	－	－	－	－

Current Period Guidance

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Dec, 2023	5,589	-811	-736	-1,962	-49.2	0	Feb 8, 2024	J-GAAP
Dec, 2024	2,452	-3,876	-3,689	-3,833	-85.0	0	Feb 6, 2025	J-GAAP
Dec, 2025 Guidance	1,858	-4,263	-4,347	-4,468	-91.7	0	Feb 6, 2025	J-GAAP
YoY	-24.2%	-10.0%	-17.8%	-16.6%	-7.8%

Quarterly Results

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Operating Profit Margin	Announce	Accounting Standards
Jan - Mar, 2024	597	-806	-727	-777	-18.0	-135.0	May 7, 2024	J-GAAP
Apr - Jun, 2024	687	-913	-754	-764	-17.2	-132.9	Aug 1, 2024	J-GAAP
Jul - Sep, 2024	614	-1,072	-1,278	-1,304	-29.1	-174.6	Oct 31, 2024	J-GAAP
Oct - Dec, 2024	554	-1,085	-930	-988	-21.9	-195.8	Feb 6, 2025	J-GAAP
Jan - Mar, 2025	264	-1,169	-1,288	-1,321	-28.0	-442.8	May 8, 2025	J-GAAP
YoY	-55.8%	-45.0%	-77.2%	-70.0%	-55.0%